Sage Journals: Discover world-class research

Abstract

French

Objective:

Depression screening among children and adolescents is controversial, and no clinical trials have evaluated benefits and harms of screening programs. A requirement for effective screening is a screening tool with demonstrated high accuracy. The objective of this systematic review was to evaluate the accuracy of depression screening instruments to detect major depressive disorder (MDD) in children and adolescents.

Method:

Data sources included the MEDLINE, MEDLINE In-Process, EMBASE, PsycINFO, HaPI, and LILACS databases from 2006 to September 30, 2015. Eligible studies compared a depression screening tool to a validated diagnostic interview for MDD and reported accuracy data for children and adolescents aged 6 to 18 years. Risk of bias was assessed with QUADAS-2.

Results:

We identified 17 studies with data on 20 depression screening tools. Few studies examined the accuracy of the same screening tools. Cut-off scores identified as optimal were inconsistent across studies. Width of 95% confidence intervals (CIs) for sensitivity ranged from 9% to 55% (median 32%), and only 1 study had a lower bound 95% CI ≥80%. For specificity, 95% CI width ranged from 2% to 27% (median 9%), and 3 studies had a lower bound ≥90%. Methodological limitations included small sample sizes, exploratory data analyses to identify optimal cut-offs, and the failure to exclude children and adolescents already diagnosed or treated for depression.

Conclusions:

There is insufficient evidence that any depression screening tool and cut-off accurately screens for MDD in children and adolescents. Screening could lead to overdiagnosis and the consumption of scarce health care resources.

Keywords

depression screening children adolescents diagnostic accuracy

Screening children and adolescents for depression is controversial. In 2009, the United States Preventive Services Task Force (USPSTF) recommended that adolescents, but not younger children, should be routinely screened for depression in primary care settings when depression care systems are in place to ensure accurate diagnosis, treatment, and follow-up.¹ The USPSTF recently reiterated this recommendation in its 2016 guideline.² By contrast, depression screening among children and adolescents has not been recommended in the United Kingdom or Canada.^3,4 No clinical trials have evaluated depression screening programs among children or adolescents,² and there are no examples of well-conducted trials among adults that have shown that depression screening would improve mental health outcomes.^5

–8

Depression screening, if initiated in practice, would involve the use of self-report questionnaires to identify children or adolescents who may have depression but have not otherwise been identified as possibly depressed by health care professionals or via self-report.^9,10 Health care professionals would need to administer a screening tool and use a predetermined cut-off score to separate children and adolescents who may have depression from those unlikely to have depression. Screening, which would be done with all children and adolescents who are not suspected of having depression, is different from case finding, which is only done with patients who health care professionals believe are at risk.¹⁰

In screening, tools must be accurate enough to identify a large proportion of unrecognized depression cases and to effectively rule out noncases to avoid unnecessary mental health assessments and the possibility of overdiagnosis and overtreatment. Thus, although screening may not improve mental health outcomes, it would consume scarce resources and further burden an already financially strapped mental health care system that struggles to provide adequate care for children and adolescents with obvious mental health needs. There is increasing attention to the problem of overdiagnosis and overtreatment across areas of medicine.¹¹ In depression screening, overdiagnosis could result in the prescription of psychotropic medications to an increased number of children, who would be exposed to the adverse effects of these medications, even if they did not experience benefits from screening.⁶

Few systematic reviews have assessed the accuracy of screening tools for detecting major depressive disorder (MDD) in children and adolescents, including data on screening tool sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). A 2009 United States Agency for Healthcare Research and Quality (AHRQ) review,¹² upon which the 2009 USPSTF guidelines¹ were based, included 9 studies, of which 5 compared a depression screening tool to a diagnosis of MDD based on a validated diagnostic interview. An updated 2016 AHRQ review,¹³ which formed the basis for the USPSTF’s recent guidelines,² identified no new eligible diagnostic accuracy studies. The 2016 AHRQ review included only a subset of 5 studies from the 2009 review, of which 3 compared a screening tool to a validated diagnostic interview as the reference standard for MDD.

A 2015 systematic review and meta-analysis¹⁴ included 52 articles on 4 commonly used depression screening tools among children and adolescents. Thirty-three studies reported diagnostic accuracy data, but approximately half were conducted with children or adolescents in mental health treatment or who were referred for mental health evaluation. Children already referred for treatment or receiving treatment, however, would not be screened in actual practice, since screening is done to identify depression among patients who have not otherwise been identified as possibly depressed. Screening accuracy should be evaluated among undiagnosed and untreated patients.¹⁵ Furthermore, in the meta-analyses conducted for each included screening tool, the authors used sensitivity and specificity results for each primary study based on an “optimal” cut-off threshold that maximized accuracy in the particular primary study, rather than using the same cut-off across included studies. For example, their meta-analysis of the accuracy of the Beck Depression Inventory (BDI) combined results from studies using cut-offs ranging from ≥11 to ≥23. As a result, synthesized accuracy values did not reflect what would be achieved in practice if the BDI were used for screening, since in practice, a cut-off must be chosen prior to screening.

The objective of the present systematic review was to evaluate the accuracy of depression screening instruments to detect MDD in children and adolescents.

Method

Detailed methods were registered in the PROSPERO prospective register of systematic reviews (CRD42012003194), and a review protocol was published.¹⁶

Search Strategy

The MEDLINE, MEDLINE In-Process, EMBASE, PsycINFO, HaPI, and LILACS databases were searched on September 30, 2015, using a peer-reviewed search strategy (Supplementary File 1). Searches included articles published January 2006 or later because the 2009 AHRQ systematic review on depression screening in children and adolescents,⁷ which included studies on the diagnostic accuracy of depression screening tools, searched through May 2006. Studies included in the 2009 and 2016 AHRQ reviews^12,13 were evaluated for possible inclusion in the present review. Search results were downloaded into the citation management database RefWorks (RefWorks-COS, Bethesda, MD, USA), and the software’s duplication check was used to identify citations retrieved from multiple sources.

Identification of Eligible Studies

Eligible articles were original studies in any language with data on children and adolescents aged 6 to 18 years, conducted in general medicine clinics, schools, and community settings. Studies of college and university populations were excluded. Studies with mixed population samples were eligible if data for children or adolescents aged 6 to 18 years were reported separately or if at least 80% of the sample were aged 18 years or younger.

Eligible diagnostic accuracy studies had to report data that allowed determination of the sensitivity, specificity, PPV, and NPV of a self-report depression screening tool compared to a current Diagnostic and Statistical Manual of Mental Disorders (DSM) diagnosis of MDD or major depressive episode (MDE) or International Classification of Diseases (ICD) depressive episode, established with a validated diagnostic interview administered within 2 weeks of the screening tool. Study authors were contacted to determine eligibility if this interval was not specified. Studies that reported only parent or teacher-completed depression measures were excluded. Studies that assessed broader diagnostic categories, such as any depressive disorder, were included only if they reported screening accuracy for MDD separately or if at least 80% of cases of depression, however defined, had a DSM diagnosis of MDD or MDE or an ICD diagnosis of depressive episode.

Two investigators independently reviewed titles/abstracts for eligibility, with full-text review of articles that were identified as potentially eligible by one or both investigators. Disagreements after full-text review were resolved by consensus. All titles/abstracts and full-text articles were available in English, Spanish, German, Portuguese, or Chinese and reviewed by investigators fluent in those languages. Non-English articles were reviewed by a single investigator.

Evaluation of Eligible Studies

Two investigators independently extracted data into a standardized spreadsheet (Supplementary File 2). Risk of bias was assessed based on published information with the revised Quality Assessment for Diagnostic Accuracy Studies–2 (QUADAS-2) tool.¹⁷ QUADAS-2 incorporates assessments of risk of bias across 4 core domains: patient selection, the index test, the reference standard, and the flow and timing of assessments (see Supplementary File 3). Any discrepancies in data extraction and risk of bias assessment were resolved by consensus.

Data Presentation and Synthesis

Data on the accuracy of screening tools were extracted with 95% confidence intervals¹⁸ based on “optimal” cut-offs identified by primary study authors. We also determined the lower bound of confidence intervals for each study, which is important for clinical decision making. For example, if at least 80% sensitivity and 90% specificity are deemed necessary to consider screening, the lower bound of 95% confidence intervals of accuracy estimates should be at least 80% for sensitivity and at least 90% for specificity.¹⁹ Studies were heterogeneous in terms of patient samples, screening tools and cut-offs, and criterion standards. Thus, results were not pooled quantitatively.

Results

Selection of Eligible Studies

Of 4608 unique titles/abstracts identified from the database search, 4444 were excluded after title/abstract review and 147 after full-text review, leaving 17 eligible articles (Figure 1).^20–36 Three additional eligible articles^37
–39 published prior to our search were identified from the 2009 AHRQ review,¹² resulting in a total of 20 included articles reporting on 17 unique studies.

Figure 1.

PRISMA flow diagram of study selection process.

Study Characteristics and Diagnostic Accuracy Results

Of the 17 included studies, 9 were conducted in school settings,^{20
–22,30
–32,37
–39} 5 in primary care or specialty medicine settings,^23
–29,36 2 in programs for adolescent mothers,^33,34 and 1 as part of a population-based longitudinal study.³⁵ Ten studies^{20,22,26–29,31,33
–35,37,38} restricted participants to adolescents (aged 12 years and older), whereas 3 studies^21,30,39 recruited study samples exclusively from high school settings but did not explicitly report on the age range of included participants. Four studies^{23–25,32,36} included both children and adolescents. Sample sizes in the 17 studies ranged from 49 to 4027 (median 290) and MDD cases from 4 to 305 (median 19). There were 2 German-language articles^25,27 (see Table 1).

Table 1.

Characteristics of Studies of Diagnostic Accuracy.

First Author, Year, Country	Age Group, y	Setting	N	Mean Age, y	Males, %	Major Depression Criterion Standard	Major Depression, n (%)	Instrument(s)	Instrument Language
BDI
Adewuya, 2007, Nigeria²⁰	13-18	School	454	15^a	58^a	K-SADS	76 (17)	BDI	NR
Barrera,^b 1988, United States³⁷	12-18	School	49	15	45	CAS	5 (10)	BDI	English
Canals, 2001, Spain³⁸	17-18	School	290	18^c	50^c	SCAN	10 (3)	BDI	Spanish
Roberts, 1991, United States³⁹	High school grades 9-12	School	1704	17	47	K-SADS	43 (3)	BDI	English
BDI-II
Araya, 2013, Chile²¹	High school grade 10	School	571^d	16	46	MINI-KIDS	301 (53)	BDI-II	Spanish
Pietsch,^e 2012, Germany²⁷	13-16	Medical clinics	314	14	40	Kinder-DIPS	21 (7)	BDI-II, BDI-FS	German
CDI
Bang, 2015, Korea²²	12-16	School	468	13	44	K-SADS	63 (13)	CDI	Korean
Butwicka, 2012, Poland²³	8-18	Inpatient diabetes care	163	14	57	K-SADS	4 (3)	CDI	Polish
CES-D
Logsdon, 2010, United States³⁴	13-18	Teen parent program	59	16	0	K-SADS	10 (17)	CES-D, CES-D-30	English
Roberts, 1991, United States³⁹	High school grades 9-12	School	1704	17	47	K-SADS	43 (3)	CES-D	English
Pietsch,^e,f 2013, Germany²⁶	13-16	Medical clinics	327	14	41	Kinder-DIPS	22 (7)	CES-D-15	German
EPDS
Logsdon, 2010, United States³⁴	13-18	Teen parent program	59	16	0	K-SADS	10 (17)	EPDS	English
Venkatesh,^g 2014, United States³³	13-18	Prenatal clinic	96	NR^h	0	KID-SCID	8 (8)	EPDS, EPDS-7, EPDS-3, EPDS-2	English
PHQ
Ganguly, 2013, India³¹	14-18	School	233	16	54	K-SADS	31 (13)	PHQ-9	English
Richardson, 2010, United States^28,29	13-17	Medical clinics	442	15	40	DISC	19 (4)	PHQ-9, PHQ-2	English
Tsai, 2014, Taiwan³⁰	High school students	School	165	17ⁱ	40ⁱ	K-SADS	18 (11)	PHQ-9, PHQ-2, PHQ-1	Chinese
MFQ-SF
Katon, 2008, United States³⁶	11-17	Primary care	1375	14	53	DISC	83^j (6)	MFQ-SF	English
Turner, 2014, United Kingdom³⁵	17-18	Population-based longitudinal study	4027	18^k	43	CIS-R	305 (8)	MFQ-SF^l	English
Other
Katon, 2008, United States³⁶	11-17	Primary care	1375	14	53	DISC	83^j (6)	ASI	English
Fruhe,^m 2012, Germany^24,25	9-12	Medical clinics	228-246	11	57	Kinder-DIPS	11ⁿ (4) to 12^o (5)	ChilD-S,^p DIKJ, DTK Dysphoria subscale	German
Ventevogel,^q 2014, Burundi³²	10-15	School	61	13	55	K-SADS	11^r (18)	DSRS	Kirundi

ASI, Childhood Anxiety Sensitivity Index; BDI, Beck Depression Inventory; BDI-II, Beck Depression Inventory–Second Edition; BDI-FS, Beck Depression Inventory–Fast Screen; CAS, Child Assessment Schedule; CDI, Children’s Depression Inventory; CES-D, Center for Epidemiological Studies Depression Scale; CES-D-15, 15-item version of the Center for Epidemiological Studies Depression Scale; CES-D-30, 30-item version of the Center for Epidemiological Studies Depression Scale; ChilD-S, Children’s Depression Screener; CIS-R, Clinical Interview Schedule–Revised form; DIKJ, German version of the Children’s Depression Inventory (Depressionsinventar für Kinder und Jugendliche); DISC, Diagnostic Interview Schedule for Children; DSRS, Depression Self-Rating Scale; DTK, Depression Test for Children (Depressionstest für Kinder); EPDS, Edinburgh Postnatal Depression Scale; EPDS-2, 2-item subscale of the Edinburgh Postnatal Depression Scale; EPDS-3, 3-item anxiety subscale of the Edinburgh Postnatal Depression Scale; EPDS-7, 7-item depressive symptoms subscale of the Edinburgh Postnatal Depression Scale; Kinder-DIPS, German structured diagnostic interview for mental disorders in children and adolescents; KID-SCID, Structured Clinical Interview for DSM-IV Childhood Diagnoses; K-SADS, Schedule for Affective Disorders and Schizophrenia for School-Age Children; MFQ-SF, Mood and Feelings Questionnaire–Short Form; MINI-KIDS, Mini International Neuropsychiatric Interview for Children and Adolescents; NR, not reported; PHQ, Patient Health Questionnaire; PHQ-1, 1-item version of Patient Health Questionnaire; PHQ-2, 2-item version of Patient Health Questionnaire; PHQ-9, 9-item version of Patient Health Questionnaire; SCAN, Schedule for Assessment of Neuropsychiatric Disorders.

^aDemographic data based on overall study sample of N = 1095, rather than the 454 adolescents included in the analyses reported in the table.

^bOf the 2 study samples reported in Barrera et al.³⁷ (i.e., psychiatric hospital inpatients and secondary school students), only the school sample was eligible for inclusion.

^cDemographic data based on overall study sample of N = 304, rather than the 290 adolescents included in the analyses reported in the table.

^dArticle reported N = 592, but diagnostic accuracy data were reported for N = 571 (sum of depressed and nondepressed cases).

^ePietsch et al.^26,27 report on the same cohort. However, the BDI-II and BDI-SF were employed as the screening instruments in Pietsch et al.,²⁷ and the CES-D-15 was employed as the screening instrument in Pietsch et al.²⁶

^fDiagnostic accuracy data were provided by the authors, as published results did not include patients with dysthymia or minor depression among noncases of major depressive disorder (MDD).

^gDiagnostic accuracy data extracted for 6 weeks postpartum visit (first administration of depression measures) for identified optimal overall cut-offs for each screening instrument, rather than for identified optimal time point cut-offs.

^hMedian age of sample = 16.

ⁱDemographic data based on overall study sample of N = 2257, rather than the 165 adolescents included in the analyses reported in the table.

^jDiagnostic accuracy data were reported for N “depressive disorders” = 83, of which there were 82 cases of MDD and 1 case of dysthymia.

^kMean age based on study sample of N = 4503 who attended the cohort assessment day, rather than the 4027 adolescents included in the analyses reported in the table.

^lShort form of Mood and Feelings Questionnaire abbreviated as “SMFQ” in Turner et al.³⁵ but reported above as “MFQ-SF” for consistency with the labeling of the same questionnaire in Katon et al.³⁶

^mFruhe et al.^24,25 report on the same cohort. However, the DSM-IV diagnostic system was employed in Fruhe et al.,²⁴ and the ICD-10 diagnostic system was employed in Fruhe et al.,²⁵ resulting in different numbers of cases of depressive disorders.

ⁿDiagnostic accuracy data were reported for N “any depressive disorder” = 11, of which there were 9 cases of MDD and 2 cases of dysthymia.

^oDiagnostic accuracy data were reported for N “any depressive disorder” = 12, of which there were 10 cases of MDD and 2 cases of dysthymia.

^pData on the accuracy of the ChilD-S in this cohort were also reported in Fruhe et al.²⁵ Per protocol, data on the accuracy of this instrument were extracted from the larger sample.

^qData were provided by the authors to correct inconsistencies in the published manuscript.

^rDiagnostic accuracy data were reported for N “depressive disorders” = 11, of which there were 9 or 10 cases of MDD and 1 or 2 cases of adjustment disorder with depressive symptoms.

The 17 included studies reported diagnostic accuracy for 20 different depression screening instruments, including subscales and alternate-length versions of standard instruments. Diagnostic accuracy was based on exploratory methods, in which the same data were used to both identify an “optimal” screening cut-off and assess accuracy in 16 studies^{20
–34,36

–39} and not specified in 1 study³⁵ (Table 2). Only 2 screening tools, the BDI (4 studies) and the Patient Health Questionnaire–9 (PHQ-9; 3 studies), had diagnostic accuracy results reported in 3 or more studies. Of all included studies, only 2 studies,^37,38 a study from the United States with 5 MDD cases and a study from Spain with 10 MDD cases, identified the same optimal cut-off for a screening tool (BDI ≥16).

Table 2.

Diagnostic Accuracy Results.

First Author, Year, Country	Instrument/Cut-off	Derivation of Cut-off	Range of Cut-offs Reported	Sensitivity, % (95% CI)	Specificity, % (95% CI)	Positive Predictive Value, % (95% CI)	Negative Predictive Value, % (95% CI)
BDI
Adewuya, 2007, Nigeria²⁰	BDI ≥18	Exploratory	≥15-21	91 (82-95)	97 (95-98)	86 (77-92)	98 (96-99)
Barrera,^a 1988, United States³⁷	BDI ≥16	Exploratory	≥6, 11, 16, 21, 26	100 (57-100)	93 (82-98)	63 (31-86)	100 (91-100)
Canals, 2001, Spain³⁸	BDI ≥16	Exploratory	≥10, 11, 14, 16	90 (60-98)	96 (93-98)	45 (26-66)	100 (98-100)
Roberts, 1991, United States³⁹	BDI ≥11	Exploratory	≥11	84 (70-92)	81 (79-83)	10 (7-14)	99 (99-100)
BDI-II
Araya, 2013, Chile²¹	BDI-II ≥17	Exploratory	≥14, 17, 20	79 (74-83)	70 (64-75)	74 (69-79)	75 (69-80)
Pietsch,^b 2012, Germany²⁷	BDI-II ≥19	Exploratory	≥16-22	86 (65-95)	93 (89-95)	46 (32-61)	99 (97-100)
	BDI-FS ≥6	Exploratory	≥4-8	81 (60-92)	90 (86-93)	37 (25-51)	99 (96-99)
CDI
Bang, 2015, Korea²²	CDI ≥20	Exploratory	≥15, 17, 20, 25	83 (71-90)	89 (85-92)	54 (44-63)	97 (95-98)
Butwicka, 2012, Poland²³	CDI ≥53	Exploratory	≥53	100 (51-100)	82 (75-87)	12 (5-27)	100 (97-100)
CES-D
Logsdon, 2010, United States³⁴	CES-D ≥16	Exploratory	≥4-31	70 (40-89)	45 (32-59)	21^c (10-37)	88^c (70-96)
	CES-D-30 ≥16	Exploratory	≥11-46	100 (72-100)	27 (16-40)	22^c (12-36)	100^c (77-100)
Roberts, 1991, United States³⁹	CES-D ≥24	Exploratory	≥24	84 (70-92)	75 (73-77)	8 (6-11)	99 (99-100)
Pietsch,^b,d 2013, Germany²⁶	CES-D-15 ≥14	Exploratory	≥14	95 (78-99)	80 (75-84)	26 (17-36)	100 (98-100)
EPDS
Logsdon, 2010, United States³⁴	EPDS ≥5	Exploratory	≥1-10	80 (49-94)	59 (45-72)	29^c (15-47)	94^c (79-98)
Venkatesh,^e 2014, United States³³	EPDS ≥9	Exploratory	≥8-10	75 (41-93)	86 (78-92)	33 (16-56)	97 (91-99)
	EPDS-7 ≥7	Exploratory	≥7, 8, 10	100 (68-100)	84 (75-90)	36 (20-57)	100 (95-100)
	EPDS-3 ≥10	Exploratory	≥10, 13	63 (31-86)	67 (57-76)	15 (6-30)	95 (87-98)
	EPDS-2 ≥10	Exploratory	≥10	88 (53-98)	80 (70-87)	28 (14-48)	99 (92-100)
PHQ
Ganguly, 2013, India³¹	PHQ-9 ≥5	Exploratory	≥1-15, 17, 21	87 (71-95)	80 (74-85)	40 (29-52)	98 (94-99)
Richardson, 2010, United States^28,29	PHQ-9 ≥11	Exploratory	≥6-13, Algorithm	89 (69-97)	78 (73-81)	15 (10-23)	99 (98-100)
	PHQ-2 ≥3	Exploratory	≥1-6	74 (51-88)	75 (71-79)	12 (7-19)	98 (96-99)
Tsai, 2014, Taiwan³⁰	PHQ-9 ≥15	Exploratory	≥9-16	72 (49-88)	95 (91-98)	65 (43-82)	97 (92-99)
	PHQ-2 ≥3	Exploratory	≥2-4	94 (74-99)	82 (75-88)	40 (26-54)	99 (96-100)
	PHQ-1 ≥2	Exploratory	≥1-3	61 (39-80)	88 (81-92)	38 (23-56)	95 (90-97)
MFQ-SF
Katon, 2008, United States³⁶	MFQ-SF ≥6	Exploratory	≥6	80 (70-87)	81 (79-83)	22 (17-27)	98 (97-99)
Turner, 2014, United Kingdom³⁵	MFQ-SF^f ≥11	Unclear	≥11	71 (66-76)	83 (82-84)	26 (23-29)	97 (97-98)
Other
Katon, 2008, United States³⁶	ASI ≥13	Exploratory	≥13	73 (63-82)	66 (63-69)	12 (10-15)	97 (96-98)
Fruhe,^g 2012, Germany^24,25	ChilD-S^h ≥11	Exploratory	≥9-12	91 (62-98)	89 (85-93)	29 (16-45)	100 (97-100)
	DIKJ ≥12	Exploratory	≥9-15	92 (65-99)	82 (76-87)	22 (13-35)	99 (97-100)
	DTK Dysphoria subscale ≥10	Exploratory	≥5-11	75 (47-91)	90 (85-93)	29 (16-47)	98 (96-99)
Ventevogel,ⁱ 2014, Burundi³²	DSRS ≥19	Exploratory	≥13, 15, 17, 19, 21	64 (35-85)	88 (76-94)	54 (29-77)	92 (80-97)

ASI, Childhood Anxiety Sensitivity Index; BDI, Beck Depression Inventory; BDI-II, Beck Depression Inventory–Second Edition; BDI-FS, Beck Depression Inventory–Fast Screen; CDI, Children’s Depression Inventory; CES-D, Center for Epidemiological Studies Depression Scale; CES-D-15, 15-item version of the Center for Epidemiological Studies Depression Scale; CES-D-30, 30-item version of the Center for Epidemiological Studies Depression Scale; ChilD-S, Children’s Depression Screener; CI, confidence interval; DIKJ, German version of the Children’s Depression Inventory (Depressionsinventar für Kinder und Jugendliche); DSRS, Depression Self-Rating Scale; DTK, Depression Test for Children (Depressionstest für Kinder); EPDS, Edinburgh Postnatal Depression Scale; EPDS-2, 2-item subscale of the Edinburgh Postnatal Depression Scale; EPDS-3, 3-item anxiety subscale of the Edinburgh Postnatal Depression Scale; EPDS-7, 7-item depressive symptoms subscale of the Edinburgh Postnatal Depression Scale; MFQ-SF, Mood and Feelings Questionnaire–Short Form; PHQ, Patient Health Questionnaire; PHQ-1, 1-item version of Patient Health Questionnaire; PHQ-2, 2-item version of Patient Health Questionnaire; PHQ-9, 9-item version of Patient Health Questionnaire.

^aOf the 2 study samples reported in Barrera et al.³⁷ (i.e., psychiatric hospital inpatients and secondary school students), only the school sample was eligible for inclusion.

^bPietsch et al.^26,27 report on the same cohort. However, the BDI-II and BDI-SF were employed as the screening instruments in Pietsch et al.,²⁷ and the CES-D-15 was employed as the screening instrument in Pietsch et al.²⁶

^cThe 2 × 2 tables (number of true positives, false positives, true negatives, and false negatives) for each screening instrument at the optimal screening threshold could not fully be replicated based on published sensitivity, specificity, positive predictive value, and negative predictive value. Study authors were unable to provide original diagnostic data to resolve discrepancies. For the EPDS ≥5, the published positive predictive value was 31% and negative predictive value 93%. For the CES-D ≥16, the published positive predictive value was 23% and negative predictive value 87%. For the CES-D-30 ≥16, the published positive predictive value was 24% and negative predictive value 100%. Confidence intervals were not reported in the published data, and negative predictive value was reported as (negative predictive value – 1).

^dDiagnostic accuracy data were provided by the authors, as published results did not include patients with dysthymia or minor depression among noncases of major depressive disorder.

^eDiagnostic accuracy data extracted for 6 weeks postpartum visit (first administration of depression measures) for identified optimal overall cut-offs for each screening instrument, rather than for identified optimal time point cut-offs.

^fShort form of Mood and Feelings Questionnaire abbreviated as “SMFQ” in Turner et al.³⁵ but reported above as “MFQ-SF” for consistency with the labeling of the same questionnaire in Katon et al.³⁶

^gFruhe et al.^24,25 report on the same cohort. However, the DSM-IV diagnostic system was employed in Fruhe et al.,²⁴ and the ICD-10 diagnostic system was employed in Fruhe et al.,²⁵ resulting in different numbers of cases of depressive disorders.

^hData on the accuracy of the ChilD-S in this cohort were also reported in Fruhe et al.²⁵ Per protocol, data on the accuracy of this instrument were extracted from the larger sample.

ⁱData were provided by the authors to correct inconsistencies in the published manuscript.

The 4 studies of the BDI^20,37
–39 included 5 to 76 MDD cases per study. “Optimal” screening cut-offs identified ranged from ≥11 to ≥18. The width of 95% confidence intervals ranged from 13% to 43% (median 30%) for sensitivity and from 3% to 16% (median 5%) for specificity. For sensitivity, only 1 study from Nigeria had a lower bound for the 95% confidence interval of at least 80%, and no studies had a lower bound ≥90%. For specificity, 3 studies had lower bounds ≥80% with 2 were ≥90%.

Three studies of the PHQ-9,^28,29,31 which included 18 to 31 MDD cases, reported optimal cut-off scores that ranged from ≥5 to ≥15. The width of the 95% confidence intervals ranged from 24% to 39% (median 28%) for sensitivity and from 7% to 11% (median 8%) for specificity. None of the studies had a lower confidence interval bound of at least 80% for sensitivity (maximum 71%), with only 1 study over 80% for specificity.

For all other screening tools with accuracy results, number of MDD cases ranged from 4 to 305 (median 20). Estimates of sensitivity were generally imprecise, with 95% confidence intervals widths of 9% to 55% (median 33%). For specificity, the width of 95% confidence intervals ranged from 2% to 27% (median 11%).

Risk of Bias

As shown in Table 3, risk of bias was high for 16 of 17 studies that did not prespecify a screening test cut-off and unclear for the remaining study.³⁵ Only 1 study³³ excluded children and adolescents with already diagnosed or treated depression who would not be screened in practice. Thus, for patient selection applicability, 15 studies were rated as unclear risk of bias, and 1 study³² was rated as high risk since 25% of study participants were already receiving psychosocial services. Risk of bias was unclear in 12 of 17 studies for methods of sample selection and unclear or high in 5 studies for the blinding of interviewers to screening test results. In addition, 6 studies were rated as unclear risk for issues related to patient flow and timing, including administration of the reference standard to only a subset of the sample, handling of missing data, and the interval between the index test and reference standard (see Supplementary File 4 for detailed QUADAS-2 coding notes for all included studies).

Table 3.

Quality Assessment of Studies of Diagnostic Accuracy (QUADAS-2).

	QUADAS-2 Domains^a
	Risk of Bias				Applicability Concerns
First Author, Year, Country	Patient Selection	Index Test	Reference Standard	Flow and Timing	Patient Selection	Index Test	Reference Standard
Adewuya, 2007, Nigeria²⁰	Low	High	Low	Unclear	Unclear	Low	Low
Araya, 2013, Chile²¹	Unclear	High	Low	Unclear	Unclear	Low	Low
Bang, 2015, Korea²²	Unclear	High	Low	Unclear	Unclear	Low	Low
Barrera, 1988, United States³⁷	Unclear	High	Unclear	Unclear	Unclear	Low	Low
Butwicka, 2012, Poland²³	Low	High	Unclear	Low	Unclear	Low	Low
Canals, 2001, Spain³⁸	Unclear	High	Low	Low	Unclear	Low	Low
Fruhe, 2012, Germany^24,25	Low	High	Low	Low	Unclear	Low	Unclear
Ganguly, 2013, India³¹	Low	High	Low	Low	Unclear	Low	Low
Katon, 2008, United States³⁶	Unclear	High	Unclear	Low	Unclear	Low	Low
Logsdon, 2010, United States³⁴	Unclear	High	Low	Low	Unclear	Low	Low
Pietsch, 2012, 2013, Germany^26,27	Low	High	Low	Low	Unclear	Low	Low
Richardson, 2010, United States^28,29	Unclear	High	High	Unclear	Unclear	Low	Low
Roberts, 1991, United States³⁹	Unclear	High	Unclear	Low	Unclear	Low	Low
Tsai, 2014, Taiwan³⁰	Unclear	High	Low	Unclear	Unclear	Low	Low
Turner, 2014, United Kingdom³⁵	Unclear	Unclear	Low	Low	Unclear	Low	Low
Venkatesh, 2014, United States³³	Unclear	High	Unclear	Low	Low	Low	Low
Ventevogel, 2014, Burundi³²	Unclear	High	Low	Low	High	Low	Unclear

^aSee Supplementary File 3 for QUADAS-2 risk of bias and applicability judgments. See Supplementary File 4 for detailed QUADAS-2 coding notes. Items are rated “low,” “high,” and “unclear” based on the QUADAS-2 guidelines and reflect the risk of bias or the degree of concern about applicability. Quality ratings were based only on published information, with the exception of information on the interval between index test and reference standard, for which information was obtained from study authors to determine study eligibility.

Excluded Studies and Comparison with Previous Systematic Reviews

Of the 9 diagnostic accuracy studies included in the 2009 AHRQ systematic review,¹² 3 were included in the present review.^37
–39 Of the other 6 studies, 3 did not administer a validated diagnostic interview as the reference standard for MDD, 1 did not administer a self-report screening instrument as the index test, and 1 compared the screening instrument to the diagnosis of any depressive disorder but did not report the number of patients diagnosed with MDD. In another study, the diagnostic interview was consistently administered more than 2 weeks after the screening instrument, per author report. Of the 5 diagnostic accuracy studies included in the 2016 AHRQ systematic review,¹³ 2 were included in the present review.^38,39 Of the other 3 studies, 1 did not administer a validated diagnostic interview as the reference standard for MDD, 1 did not administer a self-report screening instrument as the index test, and 1 consistently administered the diagnostic interview more than 2 weeks after the screening instrument, per author report (Supplementary File 5).

The 2015 Stockings et al.¹⁴ review included 33 studies that reported on the diagnostic accuracy of depression screening instruments, 5 of which were included in the present review.^{20,34,37
–39} Of these 5 studies, 3^37
–39 were also included in the 2009 AHRQ review and 2^38,39 in the 2016 AHRQ review. Sixteen studies in the Stockings et al.¹⁴ review were excluded from the present review because samples were recruited from psychiatric settings or selected on the basis of distress or depression (e.g., referred for mental health evaluation). The remaining 12 studies were excluded for other reasons, including not using a validated diagnostic interview as the reference standard, not comparing index test results to MDD diagnoses or reporting the number of patients diagnosed with MDD, or administering the screening test and diagnostic interview more than 2 weeks apart.

Discussion

The main findings of this systematic review were that there are relatively few studies on the accuracy of depression screening tools to detect MDD in children and adolescents and that existing studies have reported on a large number of different depression screening instruments in heterogeneous patient populations and settings. Only 2 screening tools, the standard versions of the BDI and PHQ-9, had diagnostic accuracy results reported in 3 or more studies.

Results on the performance of individual depression screening tools differed substantially across studies and require cautious interpretation. In all but 1 study, in which the derivation of the cut-off score was not specified,³⁵ exploratory data analysis methods were used to both set an “optimal” cut-off score and determine the accuracy of that cut-off score in the same patient sample. When data-driven methods are used to maximize diagnostic accuracy, studies generally overestimate screening tool performance, sometimes substantially.^40,41 Cut-off scores identified as “optimal” using these data-driven methods were inconsistent across included studies and varied too widely to provide health care professionals with an indication as to the most accurate cut-off score for any single screening tool. Only 2 studies included in our review^37,38 identified the same “optimal” cut-off for a screening tool (BDI ≥16). Furthermore, with only 1 exception, all included studies failed to appropriately exclude children and adolescents already diagnosed or treated for depression who would not be screened in clinical practice to identify new cases, which can also lead to inflated estimates of screening tool accuracy.¹⁵

Another important methodological consideration is that sample sizes in most included studies were small for the purpose of estimating diagnostic accuracy, with a median of 19 MDD cases per study. Estimates of screening tool sensitivity were imprecise, as reflected in wide 95% confidence intervals. Of the 20 results reported for sensitivity, only 1 study reported a lower confidence interval bound for sensitivity of at least 80%. While confidence interval widths were narrower for estimates of specificity, only 3 studies reported a lower confidence interval bound of at least 90%.

The 2016 systematic review,¹³ which was done for the USPSTF guideline,² included only 5 studies on the accuracy of depression screening tools, which represent a subset of the 9 diagnostic accuracy studies included in the 2009 USPSTF review.¹² Among the factors that may explain why the AHRQ review did not identify numerous screening accuracy studies included in the present review are the use of a single, combined search strategy for the review’s 6 key questions rather than a search designed for diagnostic test accuracy studies, the exclusion of non-English language studies and studies conducted in developing countries, the exclusion of studies conducted in specialty medicine settings, and the decision to exclude otherwise eligible studies on the basis of quality ratings.⁴² Quality exclusions were based on a list of possible quality indicators but not on a validated system for rating quality or risk of bias, such as QUADAS-2. Three of 5 studies included in the 2016 AHRQ systematic review did not meet eligibility criteria for the present review. Of the 2 studies that were included in the present review, both were rated, using QUADAS-2, as having unclear risk of bias related to patient selection and high risk related to the failure to prespecify an index test threshold.^38,39

The 2016 USPSTF guidelines suggest the use of the Patient Health Questionnaire for Adolescents (PHQ-A) and the Beck Depression Inventory–Primary Care version (BDI-PC) as screening tools for adolescents in primary care settings.² The PHQ-A is similar to the PHQ-9 for adults with minor adaptations in wording.⁴³ The BDI-PC is a 7-item depression screening tool, derived from the cognitive items of the BDI-II.⁴⁴ This recommendation was based on only 1 study of the PHQ-A⁴³ and no evidence on the accuracy of the BDI-PC in children or adolescents.¹³ The PHQ-A study⁴³ was excluded from the present review because it did not compare the PHQ-A to a validated diagnostic interview to determine MDD status.

The USPSTF recommends routine depression screening for adolescents in primary care settings when integrated depression care systems are in place.² This recommendation was made, even though no trials among children or adult patients have found that patients who are screened have better outcomes than patients who are not screened when both groups have access to similar depression treatments.^7,45 Screening is sometimes implemented even without direct evidence of effectiveness. TeenScreen, an American program based at Columbia University, urged implementation of universal depression screening for adolescents and was reportedly active at over 2800 sites in the United States and internationally before the project’s unexplained closure in 2012.⁴⁶ In Canada, several provincial governments have called for widespread depression screening in school settings and medical practices.^47
–49 In the absence of trials, the findings of the present review suggest important reasons why depression screening may be less effective than anticipated and could result in more harm than benefit. If the evidence base for depression screening tools overestimates their accuracy, the use of these questionnaires in screening programs would likely lead to high false-positive rates, unnecessary labeling, overtreatment in some cases, and the consumption of scarce mental health resources that could otherwise be used to provide better care for children and adolescents with undertreated mental health problems.⁶

A possible limitation of the systematic review is that we did not search for unpublished studies. Given the findings of the systematic review, it is unlikely that this would have changed the findings or conclusions. Another possible limitation is that we did not conduct a de novo search for studies prior to 2006 but rather used studies included in a previously published systematic review. It is possible that there could have been eligible early studies that were not identified, although the existence of multiple systematic reviews on this topic suggests that this is unlikely. Finally, although validated diagnostic interviews are considered the gold standard for establishing psychiatric diagnoses, there is not robust evidence establishing their degree of accuracy or replicability.

Conclusions

In summary, this systematic review found that there is insufficient evidence of the ability of depression screening instruments to accurately detect MDD in children and adolescents. Few studies have examined the accuracy of the same screening tools in comparable settings and populations, and there is inadequate evidence to recommend any single cut-off score for any of the instruments evaluated in the included studies. Significant methodological concerns, including small sample sizes, the use of data-driven exploratory methods to identify “optimal” cut-off scores, and the failure to exclude patients already diagnosed or treated for depression, raise concerns that existing studies may overestimate screening tool accuracy. Well-conducted studies with large sample sizes that present results across the range of possible cut-offs and follow guidance from key sources, including the Cochrane Handbook for Diagnostic Test Accuracy Meta-Analyses⁵⁰ and the STARD statement,⁵¹ are needed. The absence of any evidence from clinical trials that depression screening would improve mental health outcomes, along with the results from this systematic review, suggests that screening children and adolescents could lead to more harm than benefit and would consume scarce mental health resources that could otherwise be used to provide treatment for underserved youth with mental disorders.

Supplemental Material

The online supplementary files are available at http://cpa.sagepub.com/supplemental.

Footnotes

Acknowledgments

We thank Yue Zhao, MSc, Concordia University, Montreal, Quebec, and Linda Kwakkenbos, PhD, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, for assistance with translation. They were not compensated for their contributions.

Declaration of Conflicting Interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr. Patten reported that he received a research grant from a competition cosponsored by the Hotchkiss Brain Institute and Pfizer Canada. All other authors declare that they have no competing interests.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by a grant from the Canadian Institutes for Health Research (KA1-119795). MR was supported by a Murray R. Stalker Primary Care Research Bursary and a Mach-Gaensslen Foundation of Canada Student Grant as part of the McGill University Faculty of Medicine Research Bursary Program. BDT was supported by an Investigator Award from the Arthritis Society. No funding body had any involvement in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

References

US Preventive Services Task Force. Screening and treatment for major depressive disorder in children and adolescents: US Preventive Services Task Force recommendation statement. Pediatrics. 2009;123(4):1223–1228.

Siu

; US Preventive Services Task Force. Screening for depression in children and adolescents: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2016 Feb 9 (Epub ahead of print; DOI:10.7326/M15-2957).

MacMillan

Patterson

Wathen

. Screening for depression in primary care: recommendation statement from the Canadian Task Force on Preventive Health Care. CMAJ. 2005;172(1):33–35.

National Collaborating Centre for Mental Health. Depression in children and young people: identification and management in primary, community, and secondary care. London (UK): National Institute for Health and Clinical Excellence; 2015.

Thombs

Ziegelstein

. Does depression screening improve depression outcomes in primary care? BMJ. 2014;348:g1253.

Thombs

Coyne

Cuijpers

. Rethinking recommendations for screening for depression in primary care. CMAJ. 2012;184(4):413–418.

Thombs

Ziegelstein

Roseman

. There are no randomized controlled trials that support the United States Preventive Services Task Force guideline on screening for depression in primary care: a systematic review. BMC Med. 2014;12:13.

Thombs

Arthurs

Coronado-Montoya

. Depression screening and patient outcomes in pregnancy or postpartum: a systematic review. J Psychosom Res. 2014;76:433–446.

UK National Screening Committee. Second report of the UK National Screening Committee. London (UK): Departments of Health for England, Scotland, Northern Ireland and Wales; 2000.

10.

Raffle

Gray

. Screening: evidence and practice. London (UK): Oxford University Press; 2007.

11.

Moynihan

Doust

Henry

. Preventing overdiagnosis: How to stop harming the healthy. BMJ. 2012;344:e3502.

12.

Williams

O’Connor

Eder

. Screening for child and adolescent depression in primary care settings: a systematic evidence review for the US Preventive Services Task Force. Pediatrics. 2009;123(4):e716–e735.

13.

Forman-Hoffman

McClure

McKeeman

. Screening for major depressive disorder in children and adolescents: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2016 Feb 9 (Epub ahead of print; DOI:10.7326/M15-2259).

14.

Stockings

Degenhardt

Lee

. Symptom screening scales for detecting major depressive disorder in children and adolescents: a systematic review and meta-analysis of reliability, validity and diagnostic utility. J Affect Disord. 2015;174:447–463.

15.

Thombs

Arthurs

El-Baalbaki

. Risk of bias from inclusion of already diagnosed or treated patients in diagnostic accuracy studies of depression screening tools: a systematic review. BMJ. 2011;343:d4825.

16.

Thombs

Roseman

Kloda

. Depression screening and mental health outcomes in children and adolescents: a systematic review protocol. Syst Rev. 2012;1:58.

17.

Whiting

Rutjes

Westwood

. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529–536.

18.

Agresti

Coull

. Approximate is better than “exact” for interval estimation of binomial proportions. Am Stat. 1998;52(2):119–126.

19.

Bachmann

Puhan

ter Riet

. Sample sizes of studies on diagnostic accuracy: literature survey. BMJ. 2006;332:1127–1129.

20.

Adewuya

Ola

Aloba

. Prevalence of major depressive disorders and a validation of the Beck Depression Inventory among Nigerian adolescents. Eur Child Adolesc Psychiatry. 2007;16(5):287–292.

21.

Araya

Montero-Marin

Barroilhet

. Detecting depression among adolescents in Santiago, Chile: sex differences. BMC Psychiatry. 2013;13:122.

22.

Bang

Park

Kim

. Cut-off scores of the children’s depression inventory for screening and rating severity in Korean adolescents. Psychiatry Investig. 2015;12(1):23–28.

23.

Butwicka

Fendler

Zalepa

. Efficacy of metabolic and psychological screening for mood disorders among children with type 1 diabetes. Diabetes Care. 2012;35(11):2133–2139.

24.

Fruhe

Allgaier

Pietsch

. Children’s Depression Screener (ChilD-S): development and validation of a depression screening instrument for children in pediatric care. Child Psychiatry Hum Dev. 2012;43(1):137–151.

25.

Fruhe

Allgaier

Pietsch

. Depression screening in pediatric patients—a comparison of the concurrent validity of the German version of the Children’s Depression Inventory, the German Depression Test for Children, and the new Children’s Depression Screener [in German]. Z Kinder Jugendpsychiatr Psychother. 2012;40(3):161–169.

26.

Pietsch

Allgaier

Fruhe

. Screening for adolescent depression in paediatric care: validity of a new brief version of the Center for Epidemiological Studies Depression Scale. Child Adolesc Ment Health. 2013;18(2):76–81.

27.

Pietsch

Hoyler

Fruhe

. Early detection of major depression in paediatric care: validity of the Beck Depression Inventory–Second Edition (BDI-II) and the Beck Depression Inventory–Fast Screen for Medical Patients (BDI-FS) [in German]. Psychother Psychosom Med Psychol. 2012;62(11):418–424.

28.

Richardson

McCauley

Grossman

. Evaluation of the Patient Health Questionnaire-9 Item for detecting major depression among adolescents. Pediatrics. 2010;126(6):1117–1123.

29.

Richardson

Rockhill

Russo

. Evaluation of the PHQ-2 as a brief screen for detecting major depression among adolescents. Pediatrics. 2010;125(5):e1097–e1103.

30.

Tsai

Huang

Liu

. Patient Health Questionnaire for school-based depression screening among Chinese adolescents. Pediatrics. 2014;133(2):e402–409.

31.

Ganguly

Samanta

Roy

. Patient Health Questionnaire-9 as an effective tool for screening of depression among Indian adolescents. J Adolesc Health. 2013;52(5):546–551.

32.

Ventevogel

Komproe

Jordans

. Validation of the Kirundi versions of brief self-rating scales for common mental disorders among children in Burundi. BMC Psychiatry. 2014;14:36.

33.

Venkatesh

Zlotnick

Triche

. Accuracy of brief screening tools for identifying postpartum depression among adolescent mothers. Pediatrics. 2014;133(1):e45–e53.

34.

Logsdon

Myers

. Comparative performance of two depression screening instruments in adolescent mothers. J Womens Health (Larchmt). 2010;19(6):1123–1128.

35.

Turner

Joinson

Peters

. Validity of the Short Mood and Feelings Questionnaire in late adolescence. Psychol Assess. 2014;26(3):752–762.

36.

Katon

Russo

Richardson

. Anxiety and depression screening for youth in a primary care population. Ambul Pediatr. 2008;8(3):182–188.

37.

Barrera

Jr Garrison-Jones

. Properties of the Beck Depression Inventory as a screening instrument for adolescent depression. J Abnorm Child Psychol. 1988;16(3):263–273.

38.

Canals

Bladé

Carbajo

. The Beck Depression Inventory: psychometric characteristics and usefulness in nonclinical adolescents. Eur J Psychol Assess. 2001;17(1):63–68.

39.

Roberts

Lewinsohn

Seeley

. Screening for adolescent depression: a comparison of depression scales. J Am Acad Child Psychiatry. 1991;30(1):58–66.

40.

Ewald

. Post hoc choice of cut points introduced bias to diagnostic research. J Clin Epidemiol. 2006;59(8):798–801.

41.

Leeflang

Moons

Reitsma

. Bias in sensitivity and specificity caused by data-driven selection of optimal cutoff values: mechanisms, magnitude, and solutions. Clin Chem. 2008;54(4):729–737.

42.

Forman-Hoffman

McClure

McKeeman

. Screening for major depressive disorder among children and adolescents: a systematic review for the U.S. Preventive Services Task Force. Evidence Synthesis No. 116. AHRQ Publication No. 13-05192-EF-1. Rockville (MD): Agency for Healthcare Research and Quality; 2016.

43.

Johnson

Harris

Spitzer

. The Patient Health Questionnaire for Adolescents: validation of an instrument for the assessment of mental disorders among adolescent primary care patients. J Adolesc Health. 2002;30(3):196–204.

44.

Steer

Cavalieri

Leonard

. Use of the Beck Depression Inventory for Primary Care to screen for major depression disorders. Gen Hosp Psychiatry. 1999;21(2):106–111.

45.

Canadian Task Force on Preventive Health Care, Joffres

Jaramillo

. Recommendations on screening for depression in adults. CMAJ. 2013;185(9):775–782.

46.

Lenzer

. Controversial mental health program closes down. BMJ. 2012;345:e8100.

47.

Alberta Health and Wellness Communications. Positive futures—optimizing mental health for Alberta’s children & youth: a framework for action (2006–2016). Edmonton: Government of Alberta; 2006 [cited 2016 Feb 21]. Available from: http://www.health.alberta.ca/documents/mental-health-framework-child-06.pdf.

48.

British Columbia Guidelines and Protocols Advisory Committee. Anxiety and depression in children and youth—diagnosis and treatment. Victoria: B.C. Government; 2010 [cited 2016 Feb 21]. Available from: http://www2.gov.bc.ca/assets/gov/health/practitioner-pro/bc-guidelines/depressyouth.pdf.

49.

Manitoba Healthy Living. Reclaiming hope: Manitoba’s youth suicide prevention strategy. Winnipeg: Manitoba Government; 2008 [cited 2016 Feb 21]. Available from: http://www.gov.mb.ca/healthyliving/mh/docs/hope.pdf.

50.

Deeks

Bossuyt

Gatsonis

, editors. Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy: Version 0.9. The Cochrane Collaboration; 2013 [cited 2016 Apr 16]. Available from: http://srdta.cochrane.org/.

51.

Bossuyt

Reitsma

Bruns

. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ. 2015;351:h5527.

Accuracy of Depression Screening Tools to Detect Major Depression in Children and Adolescents: A Systematic Review

Abstract

Objective:

Method:

Results:

Conclusions:

Keywords

Method

Search Strategy

Identification of Eligible Studies

Evaluation of Eligible Studies

Data Presentation and Synthesis

Results

Selection of Eligible Studies

Study Characteristics and Diagnostic Accuracy Results

Risk of Bias

Excluded Studies and Comparison with Previous Systematic Reviews

Discussion

Conclusions

Footnotes

Acknowledgments

Declaration of Conflicting Interests

Funding

References